These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34945819)

  • 1. Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.
    Granell-Geli J; Izquierdo-Gracia C; Sellés-Rius A; Teniente-Serra A; Presas-Rodríguez S; Mansilla MJ; Brieva L; Sotoca J; Mañé-Martínez MA; Moral E; Bragado I; Goelz S; Martínez-Cáceres E; Ramo-Tello C
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
    Auer M; Bauer A; Oftring A; Rudzki D; Hegen H; Bsteh G; Di Pauli F; Berek K; Zinganell A; Berger T; Reindl M; Deisenhammer F
    CNS Drugs; 2022 Oct; 36(10):1121-1131. PubMed ID: 36173556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
    J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis.
    Cuculiza Henriksen A; Ammitzbøll C; Petersen ER; McWilliam O; Sellebjerg F; von Essen MR; Romme Christensen J
    Mult Scler Relat Disord; 2021 Jul; 52():102987. PubMed ID: 33984651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Johnsson M; Farman HH; Blennow K; Zetterberg H; Malmeström C; Axelsson M; Lycke J
    Mult Scler; 2022 Nov; 28(13):2070-2080. PubMed ID: 35856574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of natalizumab extended interval dosing in MS.
    Zhovtis Ryerson L; Li X; Goldberg JD; Hoyt T; Christensen A; Metzger RR; Kister I; Foley J
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32019876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
    Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice.
    Foley J; Xiong K; Hoyt T; Singh CM; Riddle E; de Moor C; Plavina T; Campbell N
    Mult Scler; 2023 Feb; 29(2):196-205. PubMed ID: 36377744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.
    Petersen ER; Søndergaard HB; Oturai AB; Jensen P; Sorensen PS; Sellebjerg F; Börnsen L
    Mult Scler Relat Disord; 2016 Nov; 10():66-72. PubMed ID: 27919501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Toorop AA; Rispens T; Strijbis EM; van Oosten BW; de Jong BA; Uitdehaag BM; Killestein J; van Kempen ZL
    Mult Scler; 2022 Feb; 28(2):323-326. PubMed ID: 34931887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis.
    McManus EJ; Clark KM; Frampton C; Macniven JAB; Schepel J
    Mult Scler J Exp Transl Clin; 2022; 8(1):20552173211070752. PubMed ID: 35223079
    [No Abstract]   [Full Text] [Related]  

  • 17. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
    Riancho J; Setien S; Sánchez de la Torre JR; Torres-Barquin M; Misiego M; Pérez JL; Castillo-Triviño T; Menéndez-García C; Delgado-Alvarado M
    Front Immunol; 2021; 12():614715. PubMed ID: 33841397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
    Khoy K; Mariotte D; Defer G; Petit G; Toutirais O; Le Mauff B
    Front Immunol; 2020; 11():549842. PubMed ID: 33072089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.